BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsFinancing

ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants

Related news

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BIAFbioAffinity Technologies, Inc.2026-08-14 15:07 EST

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

BIAFbioAffinity Technologies, Inc.2026-08-13 13:07 EST

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules

INBSIntelligent Bio Solutions2026-01-02 22:00 EST

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

INBSIntelligent Bio Solutions2025-12-31 22:20 EST

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

LUCDLucid Diagnostics2026-04-24 14:23 EST

Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock

LUCDLucid Diagnostics2026-04-23 12:30 EST

Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock

VRAXVirax Biolabs2025-12-04 21:05 EST

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

VRAXVirax Biolabs2025-12-03 18:53 EST

Virax Biolabs Group Limited Announces $5 Million Private Placement

View all latest news

Bluejay Diagnostics

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6...

Recent company news

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Stock data

Close
1.02 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States